Meta AnalysisID 5866
中药注射液治疗特发性肺纤维化的疗效比较：系统评价与网状Meta分析
CRD42022295916
Idiopathic pulmonary fibrosis (IPF), as a acutely or slowly into irreversible pulmonary diseases, has a severe damages to patients' lung functions, as well as deaths. Chinese medicine injections (CMIs) are widely used by
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5866
- Evidence Id
- 14424
- Core Evidence Id
- 14424
- Source Meta Analysis Id
- 5845
- Herb2 Meta Analysis Id
- HBMA005845
- Crd Id
- CRD42022295916
- Title
- Comparative efficacy of traditional Chinese medicine injections for treating idiopathic pulmonary fibrosis: A systematic review and network Meta-analysis
- Review Question
- Idiopathic pulmonary fibrosis (IPF), as a acutely or slowly into irreversible pulmonary diseases, has a severe damages to patients' lung functions, as well as deaths. Chinese medicine injections (CMIs) are widely used by clinicians in China as an adjuvant treatment in IPF. However, there was a lack of comprehensive and systematic evidence to support the beneficial effects of CMI in combination with Western medicine (WM) on IPF.
- Study Type Included
- RCT
- Condition Being Studied
- Idiopathic pulmonary fibrosis (IPF), as a type of pulmonary disease that progresses acutely or slowly into irreversible pulmonary diseases, was caused by various reasons. Healthy tissues are replaced by altered extracellular matrix, and alveolar structure is destroyed, which can lead to reduced lung compliance, interruption of gas exchange, and ultimately respiratory failure and death (Richeldi, Collard, and Jones 2017). IPF is characterized by restrictive ventilatory dysfunction, hypoxemia, and chronic progressive diffuse pulmonary fibrosis, with clinical symptoms such as progressive dyspnea, wheezing, shortness of breath, and dry cough(Lederer and Martinez 2018). Pirfenidone and nidanib are approved for the treatment of IPF because they can slow down the decline of lung function and disease progression, however, these two drugs have more adverse effects, and no reliable evidence has been seen to confirm that they have significant improvement in patients' symptoms and quality of life, and the cost of both drugs is high, which brings a heavy economic burden to patients and society(Spagnolo et al. 2021).
- Participant
- Inclusion criteria: (I) Only RCTs were included. (II) Patients enrolled in the RCTs were diagnosed with IPF, which could base on the current or past diagnostic criteria. (III) Interventions: the experimental group used CMIs or proprietary Chinese medicine combined or not combined with WM, and the control group used WM or placebo. The exclusion criteria : (I) Non-clinical randomized or non-semi-randomized controlled trials (animal studies, theoretical discussions, reviews and empirical summaries, case reports, analysis, etc.) case reports, analytical articles, etc.) (II) Patients with pulmonary fibrosis of known etiology such as systemic lupus erythematosus, bleomycin, amiodarone, radiation injury and organic dust. (III) Non-blank control and conventional WM treatment control groups.
- Animal
- Human Disease Modelled
- Intervention
- This study includes 14 CMIs applied in the clinical treatment of IPF, namely Shenfu injection (SF), Shenmai injection (SM), Ligustrazine Injection (LI), Salvia miltiorrhiza polyphenolate injection (SMP), Danhong injection (DH), Xuebijing Injection (XBJ), Shenxiong Injection (SX), Shuxuetong Injection (SXT), Rhodiola injection (RI), Huangqi injection (HQ), safflower yellow sodium chloride injection (HHS), Matrine injection (MI), Shuxuening Injection (SXN), Guanxinning Injection (GXN).
- Comparator Control
- The control group used conventional western medicine treatment, such as glucocorticoids, anti-infective drugs, cough and phlegm-reducing drugs or placebo.
- Main Outcome
- Outcomes included the clinical effectiveness rate (CER =Healing rate + markedly effective + effective rate.) Measures of effect odds ratios (ORs)
- Outcome Measure
- Additional Outcome
- Oxygen partial pressure (PaO2), Carbon dioxide partial pressure (PaCO2), Diffusing capacity of the lungs for carbon monoxide (DLCO), Forced Vital Capacity (FVC), Total lung capacity (TLC), Forced Expiratory Volume 1% (FEV1%), Forced Expiratory Volume 1/ Forced Vital Capacity (FEV1/FVC%), Type III collagen (IIIC), Transforming growth factor (TGF) Measures of effect odds ratios
- Study Method
- Systematic review
- Keyword
- Drugs, Chinese Herbal; Humans; Idiopathic Pulmonary Fibrosis; Medicine, Chinese Traditional; Network Meta-Analysis
- Contact
- Shuaiyang HUANG [email protected]
- Organisational Affiliation
- Beijing University of Traditional Chinese Medicine Beijing University of Traditional Chinese Medicine, No. 11, Beisanhuan East Road, Chaoyang District
- Funding Source
- No Funding
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-12-19
- Registration Date
- 2022-01-19
- Anticipated Start Date
- 2021-12-03
- Anticipated Completion Date
- 2022-01-26
- Title Cn
- 中药注射液治疗特发性肺纤维化的疗效比较：系统评价与网状Meta分析
- Title En
- Comparative efficacy of traditional Chinese medicine injections for treating idiopathic pulmonary fibrosis: A systematic review and network Meta-analysis
- Bilingual Status
- complete